Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMC Life Sciences BhdXKLS:0101 60 Receivables Turnover is 1.47 as of Mar. 2026. GuruFocus rates XKLS:0101 with a GF Score™ of 60/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 660 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks worse than 58.33% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TMC Life Sciences Bhd's Revenue for the
three
months ended in Mar. 2026 was RM89.7 Mil. TMC Life Sciences Bhd's average Accounts Receivable for the
three
months ended in Mar. 2026 was RM61.0 Mil.
Hence, TMC Life Sciences Bhd's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.47.
TMC Life Sciences Bhd (XKLS:0101) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
TMC Life Sciences Bhd Receivables Turnover Related Terms
TMC Life Sciences Bhd Receivables Turnover Historical Data
* Premium members only.
The historical data trend for TMC Life Sciences Bhd's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0101 vs HCA, THC, DVA: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd (XKLS:0101) has a Receivables Turnover of 1.47 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TMC Life Sciences Bhd and its competitors. According to the industry distribution chart, TMC Life Sciences Bhd ranks #385 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 58.3%.
Is TMC Life Sciences Bhd's Receivables Turnover too high?
TMC Life Sciences Bhd's current Receivables Turnover is 1.47. The Healthcare Providers & Services industry median Receivables Turnover is 7.75. TMC Life Sciences Bhd's value of 1.47 is 81% below this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #385 out of 660 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, TMC Life Sciences Bhd has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's Receivables Turnover compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #385 out of 660 companies for Receivables Turnover. This places TMC Life Sciences Bhd in the lower half of its industry. The industry median Receivables Turnover is 7.75. TMC Life Sciences Bhd's value of 1.47 is 81% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current Receivables Turnover of 1.47 is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current Receivables Turnover is 1.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.47 — trading 24.2% below its estimated fair value. The current Receivables Turnover is 1.47 and 81% below the Healthcare Providers & Services industry median of 7.75. TMC Life Sciences Bhd's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current Receivables Turnover is 1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.47 is trading 24.2% below its estimated GF Value™ of RM0.62.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
Receivables Turnover: 1.47
GF Value™: RM0.62 vs. price of RM0.47 (24.2% below fair value)
Industry Position: 81% below the Healthcare Providers & Services median (#385 of 660)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
60GF Score
Get the complete analysis for XKLS:0101
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
